Theravance Biopharma, Inc.TBPHNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank0
3Y CAGR-18.9%
5Y CAGR-32.2%
Year-over-Year Change
Research and development spending
3Y CAGR
-18.9%/yr
vs -23.2%/yr prior
5Y CAGR
-32.2%/yr
Recent acceleration
Acceleration
+4.3pp
Accelerating
Percentile
P0
Near historical low
vs 5Y Ago
0.1x
Contraction
Streak
5 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $37.41M | -0.6% |
| 2024 | $37.64M | -18.8% |
| 2023 | $46.34M | -33.9% |
| 2022 | $70.07M | -65.2% |
| 2021 | $201.55M | -22.8% |
| 2020 | $260.95M | +19.0% |
| 2019 | $219.25M | +8.9% |
| 2018 | $201.35M | +15.8% |
| 2017 | $173.89M | +22.7% |
| 2016 | $141.71M | - |